DB

Differentia Bio

www.differentiabio.com link_icon

Differentia Bio Inc. - Company Market Research Report



Company Overview



Name and Mission of the Company


  • Name: Differentia Bio Inc.

  • Mission: To enable biopharmaceutical companies through knowledge-empowered modeling, leveraging proprietary data and AI/ML analytics for a deeper understanding of biological systems. Their services accelerate the discovery and delivery of safe and effective therapies that improve healthcare outcomes worldwide.


Founding Details


  • When was the company founded and by whom: No information is available.

  • Key people in the company:

  • Kas Subramanian - CEO

  • Atefeh Kazeroonian - Mechanistic Modeling VP

  • Catherine Sherwin - Clinical Pharmacology & Pharmacometrics VP

  • Chris Reinert - COO

  • Lorenz Huebner - VP Customer Solutions

  • Rajeev Kumar - Mechanistic Modeling Senior Director

  • Simon Junankar - Scientific Affairs Director

  • Where is the company headquartered: 611 Gateway Blvd, Suite 120, South San Francisco, California, 94080, USA

  • Number of Employees: No information is available.

  • Revenue of the Company: No information is available.

  • What is the company known for: The company is known for its modeling & simulation services to biopharmaceutical companies, delivering knowledge-based insights to improve drug development outcomes.


Products



List of Products and Services



1. Preclinical Services
  • Description:

  • Target identification and validation

  • Model-supported lead optimization and candidate selection

  • Best-in-class property identification and competitive benchmarking

  • Key Features:

  • Accelerates candidate target identification by focusing on clinically relevant pathways

  • Leverages models to evaluate candidate molecules against known therapies

  • Supports explicit optimization objectives for lead optimization cycles


2. Translational Services
  • Description:

  • Model-based characterization of the therapeutic index

  • Prediction of human efficacious dose and safe starting dose

  • Model-based design of preclinical and phase I studies

  • Key Features:

  • Models help to translate efficacy data into MABEL dose and safety data into NOAEL predictions

  • Ensures smoother transition from preclinical to clinical phases


3. Clinical Services
  • Description:

  • Population PK and PD analysis

  • Selection of RP2D and design of clinical Phase II/III trials

  • Patient stratification and biomarker selection

  • Model-based design of clinical studies

  • Key Features:

  • Supports dose predictions for ethnic bridging, pediatrics, and special populations

  • Biopharmaceutical companies use models to power trials appropriately and identify the right data


Detailed Product Features


  • Mechanistic Modeling & QSP

  • Supports all stages of drug development from discovery to clinical stages

  • Prioritizes targets, identifies biomarkers, and tests combination therapy hypotheses

  • Enables modeling support for therapeutic modalities


  • Clinical Pharmacology and Pharmacometrics

  • Covers clinical phases I, II, III

  • Designs dose selection strategy, PK analysis, and ADME studies

  • Leverages PK, PD, and MIDD methodologies


Recent Developments



Recent Company Developments


  • What are the recent developments in the company: No information is available.


  • What are the new products launched: No information is available.


  • What are the new features added to the existing products: No information is available.


  • Any new partnerships: No information is available.


Conclusion


This report details the critical aspects of Differentia Bio Inc., focusing on its comprehensive modeling and simulation services tailored for biopharmaceutical companies. For specific data on revenue, employees, recent developments, and other detailed metrics, further investigation is recommended.